Alnylam's Cidebsirna reduces liver fat by up to 80% sustained through 36 weeks
ALNY•Alnylam said Cidebsirna reduced liver fat by up to 80%, with the effect sustained through 36 weeks. Collaborator Regeneron advanced the drug after promising first-in-human results in patients with MASLD.
1. First-in-human results
Alnylam said its collaborator Regeneron advanced Cidebsirna after promising first-in-human results in patients with MASLD. The drug reduced liver fat by up to 80%, with the reduction sustained through 36 weeks.
